Dawn Dufield, PhD, Senior Director of Biopharmaceutical LC-MS/MS Services at KCAS, has been invited to lead a workshop discussion session on Lipidomics at an upcoming Gordon Research Conference from August 7-12 in Newry, ME. The event will be a week long conference highlighting recent developments in standardization, omics integration, and state-of-the-art technologies and their impact on applications to study human health and disease.
From the Gordon Research Conference website:
In this Gordon Conference series, we will highlight recent developments in standardization, omics integration, and state-of-the-art technologies and their impact on applications to study human health and disease. The time is critical to set the future cornerstones in how to powerfully, adequately, and transparently define the lipidomics rules of new and existing platforms in basic research, and most importantly, in a regulatory environment. Overall, the future of lipidomics in the clinical and biological realms will be discussed at this conference, aligning with other ongoing consortia, with an anticipated active involvement of researchers across all important arenas (academic, industry, government) and different stages of their career (established and young scientists).
The field of lipidomics centers on the comprehensive study of lipid or fat molecules in cells, tissues, and biofluids. This diagnostic approach studies quantifiable information about the content, profile and interaction of lipids, which are of the most common biological molecules in humans. The lipidome of human plasma or eukaryotic cells contains thousands of lipid entities that structurally and chemically play fundamental roles in cellular membrane regulation, energy storage, or become precursors to bioactive metabolites. Alterations in the lipid content therefore becomes indicative of certain biological, medical, disease and health states. Driven by high expectation in its ability to afford new opportunities for studying lipids in health and disease, and in many other fields of research, lipidomics has meticulously emerged over the past decade. In fact, initial evidence of its power is emerging that draws major attention to the field, resulting in a wave of interest in adopting lipidomics capabilities across research communities. The full release of lipidomics now waits on the standardization of the field.
Click here to learn more about the conference and the session Dufield will be leading.
The discussion Dufield will be leading is entitled “Clinical and Translational Lipidomics” and it will focus on the future of lipidomics in the clinical and biological realms.
“KCAS has a lot of expertise in this area.” says Dufield “We’ve worked on a number of lipid projects – glycosphingolipids, ceramides, and other different types of lipids used in researching Alzheimer’s, Parkinson’s, and other neuro science-related research, for instance. We’ve done many short chain fatty acids and some other related elements, so I believe – both from a learning perspective and an expert contribution side – it’s a good fit for KCAS to lead this session.”
If you would like to learn more about this conference and/or the session Dawn Dufield, PhD will be leading, please click here. If you would like to set up a time to speak directly with Dufield or any of our other bioanalytical specialists here at KCAS, please use the form below.